Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics have entered into a partnership agreement to advance clinical validation of Exosome's blood and cerebrospinal fluid (CSF) - based molecular diagnostics technology in brain cancer.
The Exosome RNA biofluid-based diagnostic technology is being used for early identification, progression monitoring and disease risk stratification in common form of brain cancer, glioma.
The collaboration brings clinicians, researchers and industry participants together to develop a high-quality disease-specific RNA, which is harvested from exosomes found in blood and cerebrospinal fluid.
Accelerate Brain Cancer Cure CEO Max Wallace said the ability to identify and track specific pathway mutations over time could improve brain cancer patient care.
Exosome Diagnostics CEO James McCullough said accessing the stable RNA contained in blood and CSF exosomes gives them a significant advantage when it comes to detecting and understanding genetic changes inside the brain compartment caused by a tumor or immune response without the need for surgical biopsy.
"Collaborating with ABC2 helps ensure we are asking the right questions and structuring our clinical studies properly from the beginning for this first critical disease target in our neuro-degenerative disease program," McCullough said.